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Abstract Due to lack of effective therapies, muscular dystro-
phies became a focus for gene therapy. Multiple pre-clinical
studies have shown successful restoration of dystrofin and
dysferlin by RNA editing both in vivo and in vitro, but possi-
bility of a clinical translation is still obscure. A number of new
chemicals are being studied, and a search for new techniques
is ongoing. This work is intended to give a brief overview of
the current state of the RNA editing for treating muscular
dystrophies.
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AAV Adeno-associated virus
ES Exon-skipping
TS Trans-splicing
DMD Duchenne muscular dystrophy
BMD Becker muscular dystrophy
LGMD2B Limb girdle muscular dystrophy type 2B
1 Introduction
RNA editing is a method that allows to remove or add genetic
sequences mostly in the process of pre-mRNA splicing to
obtain mRNA with no mutation and restored open reading
frame, which can support, as the result, translation of a func-
tional protein. Two main approaches for RNA editing are
trans-splicing (TS) and exon skipping (ES). These methods
are relatively well-studied in human cells and researchers are
able to manipulate with small genetic constructs; therefore,
small coding capacity, but safe and widely used AAV-
vectors (for TS) or synthetic oligonucleotides (for ES), could
be used. These approaches have become promising tools to
correct mutations in genes responsible for a number of
inherited diseases. Hemophilia A, spinal muscular atrophy,
dystrophic epidermolysis bullosa, cystic fibrosis, Duchenne
muscular dystrophy, dysferlinopathy (LGMD2b and
Miyoshi myopathy), ataxia telangiectasia, neurofibromatosis
(types 1 and 2), Pelizaeus–Merzbacher disease etc., have been
successfully corrected in vitro or in vivo [1]. Muscular dys-
trophies are among the most prevalent inherited diseases caus-
ing premature death and disability, and RNA editing technol-
ogy is being widely studied as a possible treatment.
2 Muscular Dystrophies
Muscular dystrophies are inherited myogenic disorders char-
acterized by progressive muscle wasting and weakness of var-
iable distribution and severity [2]. The chain Bgene – protein –
function – disease^ underlies the pathogenesis of these dis-
eases. Various mutations in gene encoding muscle proteins
(missens mutations, nonsense mutations, codon repeats etc.,)
lead to the gene structure changes which result in a protein
structural and functional changes or absence of a protein. The
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most affected proteins are dystrophin, dysferlin, integrins alfa-
7 and alfa-9, caveolin 3, calpain 3, collagen type VI, lamins
A/C, merosin, sarcoglycan, selenoprotein N1, emerin, and
cholin kinase beta. Among the most prevalent—Duchenne
muscular dystrophy (DMD) and dysferlinopathy (Miyoshi
and LGMD2B)—are caused by mutations in DMD
(dystrophin) and DYSF (dysferlin) genes, respectively [3].
DMD is a life-threatening disease, found in 1 out of 3500
boys. One out of 30,000 boys is being diagnosed with a milder
form, Bekker myodystrophy, with a manifestation age of
about 20 years old. DMD manifests at 2–5 years and rapidly
leads to a proximal muscle weakness and a premature death
due to a heart and lung muscle deficiency. Less prevalent and
dramatic, though socially significant and leading to disability
at an employable age, is dysferlinopathy with prevalence of
0.5–1 in 200,000 newborns. It includes a spectrum of muscle
diseases characterized by two main phenotypes: Miyoshi my-
opathy with primarily distal weakness and limb-girdle muscu-
lar dystrophy type 2B (LGMD2B) with primarily proximal
weakness. Other phenotypes are scapuloperoneal syndrome,
distal myopathy with anterior tibial onset, elevated serum cre-
atine kinase concentration only, and congenital muscular dys-
trophy [4].
There is no effective treatment for these diseases yet, and
the only method that is able to implement etiotropic treatment
is an intervention into the gene expression process which in-
cludes recombinant cDNA transfection, genomic DNA
editing technologies, and mRNA editing. Most of these ap-
proaches are limited due to several reasons: small coding ca-
pacity of AAV vector (which is considered one of the safest
viral vectors for clinical application)—under 4.7 kb—cannot
accommodate large size of gene encoding muscle proteins.
DMD is the largest gene found in nature, measuring 2.4 mil-
lion base pairs and consisting of 79 exons. DYSF gene has 55
exons and 6.2 thousand base pair nucleotides in an open read-
ing frame [5]. Thereby, RNA editing has a good potential due
to the relatively small size of therapeutic molecules and has an
ability to use only one vector (no need of co-transfection), and
it is affecting only those cells where a protein’s mRNA is
being synthesized.
3 Exon Skipping
ES is a process that allows to bypass a mutated part of mRNA
by antisense oligonucleotides (AONs) to restore the reading
frame of a gene. As the result of ES, truncated mRNA and
thereafter truncated protein are being produced, unless AONs
are targeted to splicing silencers, pseudo or nonsense
exons [6, 7]. Thus, ES is only effective when protein
structural changes do not affect its functionality.
AONs are complex molecules targeted to particular com-
plimentary regions of pre-mRNA. To date, a number of AONs
have been developed with increased specificity and stability:
2’OMePS (2’O-methyl-phosphorothioate oligonucleotide),
PMO (phosphorodiamidate morpholino oligomer), LNA
(locked nucleic acid), PNA (peptide nucleic acid), tcDNA
(tricyclo DNA), PPMO (peptide-conjugated PMO), Pip-
PMO (PMO internalization peptide-conjugated PMO), and
vPMO (vivo-morpholino). PMO and 2’OMePS studies have
reached clinical trial stage, but none has been approved yet.
AONs are promising therapeutic agents for DMD as they
can restore the open reading frame of mutant DMD gene. The
structure of dystrophin allows deletion of internal parts of the
protein without a significant loss of functionality and protein
synthesis; therefore, exon skipping could produce partially
functional dystrophin protein isoforms in skeletal muscle
and convert the DMD phenotype into a milder BMD pheno-
type. Studies of exon skipping have shown that it is theoreti-
cally applicable in up to 83% of all DMD mutations [8];
moreover, multiexon skipping from exons 45 through 55
could rescue phenotype in up to 63% of patients with
Duchenne muscular dystrophy [9].
To date, eight constructs have been studied in phases
1–3 clinical trials. They are Kyndrisa (Drisapersen)
(2’OMePS targeting exon 51, phase 3, NCT01803412)
by BioMarin Pharmaceutical, USA; PRO044, PRO045,
PRO053 (2 ’OMePS target ing exon 44 (phase 2,
NCT02329769), 45 (phase 2b NCT01826474), 53 (Phase 1/2
NCT01957059) respectively) by BioMarin Pharmaceutical;
Eteplirsen (PMO targeting exon 51, phase 3 NCT02255552)
by Sarepta Therapeutics, USA; SRP-4045, SRP-4053 (PMOs
targeting exon 45 (phase 1/2, NCT02530905) and exon 53
(phase 1/2 NCT02310906) respectively) by Sarepta
Therapeutics; NS-065/NCNP-01 (PMO targeting exon 53,
phase 1, NCT02081625) National Center of Neurology and
Psychiatry, Japan [10]. All studies have been suspended due
to low efficiency of abovementioned AONs when applied in
humans. Registration of applications by Kyndrisa and
Eteplirsen has been rejected by the Food and Drug
Administration (USA) due to the same reasons. In 2016,
BioMarin has announced discontinuation of their current re-
search on experimental drugs for DMD, but will continue to
explore the development of the next generation oligonu-
cleotides [11].Later this year FDA granted accelerated
approval to Exondys 51 (eteplirsen). Under the accel-
erated approval provisions, the FDA is requiring Sarepta
Therapeutics to conduct a clinical trial to confirm the
drug’s clinical benefit. The required study is designed to
assess whether Exondys 51 improves motor function of
DMD patients with a confirmed mutation of the dystro-
phin gene amenable to exon 51 skipping. If the trial
fails to verify clinical benefit, the FDA may initiate
proceedings to withdraw approval of the drug [12].
Despite failure of most of the clinical trials of AONs, some
molecules demonstrated promising results in ongoing pre-
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clinical research. According to Goyenvalle et al., a systemic
delivery of tcDNA-AONs promotes a high degree of rescue of
dystrophin expression in skeletal muscles, the heart, and, to a
lesser extent, the brain [13]; LNA-modified AONs exhibit
better mismatch discrimination and high resistance to nucle-
ases [14]. The work of Peccate et al. demonstrated that the
PPMO pre-treatment allowed efficient maintenance of AAV
genomes in mdx muscles and enhanced the AAV-U7 therapy
effect by ten-fold increase of the protein level after 6 months.
PPMO pre-treatment was also beneficial to AAV-mediated
gene therapy with transfer of micro-dystrophin cDNA into
muscles [15].
Thus, ES has become a common approach in DMD
treatment; however, its application in DYSF gene correction
is limited. Unlike dystrophin, truncated and functional
dysferlin has been demonstrated only in one study. Exon 32
skipping has allowed to obtain functional dysferlin in myo-
blasts generated from patient MyoD transduced fibroblasts
[16]. New exon skipping targets are being assessed by in silico
modeling [17]; however, no results have been published yet.
4 Spliceosome-Mediated RNATrans-Splicing
RNA trans-splicing is a process in which exons originating
from two distinct pre-mRNA molecules are joined, and single
chimeric mRNA molecule is produced. There are currently
three approaches for TS: endonuclease, ribozyme-mediated,
and spliceosome-mediated trans-splicing. Spliceosome-
mediated trans-splicing is the most well studied, and along
with other types, it could be induced artificially.
Spliceosome-mediated RNA trans-splicing (SMaRT) al-
lows to reprogram RNA splicing process to substitute a mu-
tation containing exon to a normal one via pre-trans-splicing
molecules (PTMs) delivered by viral vectors (usually AAV).
PTMs are complex molecules consisting of three domains:
binding domain, targeted to an exon of interest; splicing do-
main, initiating splicing process on the PTM; and a coding
domain, a sequence, coding new exon. Three types of
SMaRT have been described: 1) 3′ TS, the most well-studied
type, occurs when 3′ splice site of PTM and a 5′ target site are
linked together; 2) 5′ TS, which is opposite to 3′ TS and is less
studied; and 3) internal type, when PTM has both 3′ and 5′
binding domains in its structure [1].
Pre-clinical studies have shown SMaRT to successfully
correct mutations causing such diseases as hemophilia A, spi-
nal muscular atrophy, dystrophic epidermolysis bullosa, and
cystic fibrosis in vivo. [1].
DMD pre-mRNA editing has been performed by Lorain
et al. in vitro by using co-transfection of PTMs along with a
reporter minigene containing part of the dystrophin gene har-
boring the stop-codonmutation found in the mdxmouse mod-
el of DMD. Accurate and efficient trans-splicing of up to 30%
of the transcripts encoded by the co-transfected minigene has
been achieved.
Correction ofDYSF gene has been described in two works.
Monjaret et al. had used RNA trans-splicing molecules de-
signed to target the 3′ end of human dysferlin pre-mRNA
transcripts (in HER911 cells). Trans-splicing of pre-mRNA
generated fromminigene constructs and from the endogenous
genes was achieved. However, in addition to corrected
mRNAs, they detected undesirable PTMs spliced directly
from open reading frames present on themolecule or associated
with internal alternative cis-splicing [18]. Philippi et al. had
successfully trans-spliced DYSF gene pre-mRNA in vitro in
human LGMD2Bmyoblasts as well as in vivo in skeletal mus-
cle of wild-type and Dysf(−/−) mice [19]. This was the first
demonstration of Dysf protein rescue by SmaRT in vivo.
Over the recent years, there has been great progress in
muscular dystrophy therapy development. Despite failure of
clinical trials so far, new promising molecules for ES are being
intensively studied both by academia and industry. To date, no
clinical trials involving TS have been announced; therefore,
its efficiency in patients is not clear and its safety needs to be
assessed. Though new DNA editing technologies (CRISPR/
Cas systems and NgAgo-gDNA) are considered as new ap-
proaches for gene therapy in human, RNA editing should be
studied more thoroughly. RNA editing is a versatile tool for
mutation corrections, which can be used independently or in
combination with other gene therapeutic techniques to boost
its efficiency.
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